Get the Stockscreener App
64.78
11.20%
6.525
After Hours:
67.87
3.095
+4.78%
Disc Medicine Inc stock is traded at $64.78, with a volume of 894.07K.
It is up +11.20% in the last 24 hours and up +29.73% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
See More
Previous Close:
$58.25
Open:
$60.07
24h Volume:
894.07K
Relative Volume:
3.57
Market Cap:
$1.93B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-16.36
EPS:
-3.9598
Net Cash Flow:
$-74.38M
1W Performance:
+41.12%
1M Performance:
+29.73%
6M Performance:
+117.44%
1Y Performance:
+33.06%
1-Day Range:
$57.91
$65.25
1-Week Range:
$44.81
$65.25
52-Week Range:
$25.60
$77.60
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine (NASDAQ:IRON) Stock Price Up 7%Here's Why - MarketBeat
Disc Medicine (NASDAQ:IRON) Earns Buy Rating from HC Wainwright - MarketBeat
Scotiabank upgrades Disc Medicine shares target on trial update By Investing.com - Investing.com UK
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine to Present Complete DISC-0974 Trial Data, Portfolio Updates at ASH 2024 | IRON Stock News - StockTitan
Disc Medicine (NASDAQ:IRON) Upgraded to Overweight at Morgan Stanley - MarketBeat
Wedbush Reaffirms Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc over the moon as FDA urges Apollo bid with bitopertin in EPP - BioWorld Online
FDA aligns with Disc Medicine on EPP treatment study By Investing.com - Investing.com Canada
Disc Medicine stock rallies 26% on FDA update for bitopertin (update) - Seeking Alpha
Disc Medicine Shares Rise After Positive Feedback From FDA - MarketWatch
Disc Medicine (NASDAQ:IRON) Shares Gap UpShould You Buy? - MarketBeat
Disc Medicine leaps as it gets positive FDA feedback - The Pharma Letter
Raymond James increases Disc Medicine shares to Strong Buy on new drug - Investing.com UK
Disc Medicine (NASDAQ:IRON) Rating Increased to Strong-Buy at Raymond James - MarketBeat
FDA aligns with Disc Medicine on EPP treatment study - Investing.com
Disc Medicine Gains FDA Support for Bitopertin Trial - TipRanks
Disc Medicine Announces Successful End of Phase 2 Meeting - GlobeNewswire
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval - StockTitan
(IRON) Technical Data - Stock Traders Daily
Disc Medicine to Host Conference Call on End of Phase 2 FDA - GlobeNewswire
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - StockTitan
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Update - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Short Interest Down 6.9% in October - MarketBeat
Disc Medicine’s (IRON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Recent Investment Analysts’ Ratings Updates for Disc Medicine (IRON) - Defense World
Disc Medicine's SWOT analysis: promising pipeline drives stock outlook - Investing.com India
Disc Medicine's (IRON) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Disc Medicine retains stock target, buy rating with positive CKD study data - Investing.com UK
Disc Medicine Presents Positive Data from SAD Cohorts of a - GlobeNewswire
Disc Medicine Reports Progress in Anemia Treatment Study By Investing.com - Investing.com Australia
Disc Medicine Reports Progress in Anemia Treatment Study - Investing.com
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week - The Manila Times
Disc Medicine's SWOT analysis: stock poised for growth amid clinical progress - Investing.com Australia
Disc Medicine's SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Jefferies bullish on Disc Medicine, calls bitopertin a blockbuster in the making - Investing.com Canada
Disc Medicine stock draws but at Jefferies (IRON:NASDAQ) - Seeking Alpha
Disc Medicine appoints new chief technical officer - Investing.com
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer - The Manila Times
Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
How To Trade (IRON) - Stock Traders Daily
Sanctuary Advisors LLC Takes $68,000 Position in TCW Strategic Income Fund, Inc. (NYSE:TSI) - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
DocuSign (NASDAQ:DOCU) & Freshworks (NASDAQ:FRSH) Critical Review - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Disc Medicine (NASDAQ:IRON) - Defense World
Scotiabank Begins Coverage on Disc Medicine (NASDAQ:IRON) - MarketBeat
Tax incentives announced for life science companies in Mass. - WWLP.com
Cantor Fitzgerald Reiterates "Overweight" Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Degenerative Disc Disease Treatment Market Growth Analysis with Investment Opportunities For 2024-2033 - EIN News
Marshall Wace LLP Sells 2,179 Shares of Twin Disc, Incorporated (NASDAQ:TWIN) - Defense World
The Manufacturers Life Insurance Company Grows Stake in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):